Literature DB >> 20302837

Chapter 12- Brain as an HIV sequestered site: Use of nanoparticles as a therapeutic option.

Christopher J Destache1.   

Abstract

Patients infected with human immunodeficiency virus (HIV) are at increased risk to develop neurocognitive problems. HIV crosses the blood-brain barrier (BBB) through a variety of means. Once within the brain tissue, HIV stimulates immunoactivation and inflammation that lead to neuronal loss. This review discusses the pathophysiology of HIV within the brain and the treatment modalities used to prevent neurocognitive problems from developing. Modalities that prevent antiretroviral drugs from crossing into the central nervous system and reducing viral load are also discussed. Finally, since drug penetration across the BBB is reduced, the use of nanoparticles as a treatment modality to increase BBB penetration may be an option worth further exploration. Copyright 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20302837     DOI: 10.1016/S0079-6123(08)80012-X

Source DB:  PubMed          Journal:  Prog Brain Res        ISSN: 0079-6123            Impact factor:   2.453


  5 in total

Review 1.  The blood-testis barrier and its implications for male contraception.

Authors:  C Yan Cheng; Dolores D Mruk
Journal:  Pharmacol Rev       Date:  2011-10-28       Impact factor: 25.468

Review 2.  Development of HIV reservoir targeted long acting nanoformulated antiretroviral therapies.

Authors:  Benson J Edagwa; Tian Zhou; JoEllyn M McMillan; Xin-Ming Liu; Howard E Gendelman
Journal:  Curr Med Chem       Date:  2014       Impact factor: 4.530

3.  Randomized trial of minocycline in the treatment of HIV-associated cognitive impairment.

Authors:  Noeline Nakasujja; Sachiko Miyahara; Scott Evans; Anthony Lee; Seggane Musisi; Elly Katabira; Kevin Robertson; Allan Ronald; David B Clifford; Ned Sacktor
Journal:  Neurology       Date:  2012-12-26       Impact factor: 9.910

4.  Darunavir-cobicistat versus lopinavir-ritonavir in the treatment of COVID-19 infection (DOLCI): A multicenter observational study.

Authors:  Eman Zeyad I Elmekaty; Rim Alibrahim; Rania Hassanin; Sitelbanat Eltaib; Ahmed Elsayed; Fatima Rustom; Mohamed Izham Mohamed Ibrahim; Mohammed Abu Khattab; Hussam Al Soub; Muna Al Maslamani; Abdullatif Al-Khal
Journal:  PLoS One       Date:  2022-05-04       Impact factor: 3.752

Review 5.  Nanoparticle-based drug delivery to improve the efficacy of antiretroviral therapy in the central nervous system.

Authors:  Maria João Gomes; José das Neves; Bruno Sarmento
Journal:  Int J Nanomedicine       Date:  2014-04-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.